Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting
The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.
- The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.
- Others include a retrospective chart review on the use of LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% in refractive surgery and numerous presentations focused on Bausch + Lomb surgical IOL pipeline programs.
- New data from the Bausch + Lomb Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study will also be presented.
- “Clinical Evaluation of the Outcomes of Two Preloaded Monofocal IOLs Implanted Bilaterally in Cataract Patients.” Shultz et al.